Guide contents
Open in calculatorCompound briefing
Semax is a synthetic heptapeptide analogue of ACTH(4-10), developed in Russia and used clinically there for stroke recovery, cognitive enhancement and optic-nerve disorders. It is one of the most extensively studied nootropic peptides, with documented neuroprotective and neurotrophic effects.
The research question
Semax research spans ischaemic injury, neurotrophic signalling and attention. Outcomes in neurological injury models cannot simply be transferred to healthy-subject cognitive research.
Mechanism & research themes
Upregulates BDNF and NGF expression, modulates dopaminergic and serotonergic transmission, and inhibits enkephalin-degrading enzymes. Demonstrates neuroprotective effects via reduced excitotoxicity and oxidative stress.
Significant neuroprotection in ischaemic stroke research
Sustained BDNF and NGF upregulation supporting neuroplasticity
Improved attention, working memory and executive function
Improved recovery outcomes in optic-nerve and CNS-injury research
Modulation of dopaminergic systems supporting motivation and mood
Favourable safety profile in Russian clinical use
These are research themes reported across the literature, not established benefits or indications.
Evidence assessment
Clinical use and trials are reported mainly in Russian-language literature. Broader conclusions require independent replication and clear separation of neurological indications from general cognitive claims.
What to look for
Controlled design, a defined preparation, clinically relevant endpoints and independent replication carry more weight than a single mechanism study.
What not to assume
A plausible pathway does not establish efficacy. Results across different routes, formulations and populations are not automatically interchangeable.
Protocol literature
Commonly referenced research protocols use 250–600mcg intranasally 1–3× daily, or subcutaneously at similar doses. Cycles typically run 2–4 weeks with breaks. Higher doses (up to 1200mcg/day) appear in stroke-recovery research.
Reported persistence
Plasma half-life is very short (minutes), but CNS effects persist for hours due to BDNF/NGF upregulation cascades.
Calculator starting point
0.3 mg per reference dose
5 doses per week · 4-week cycle
2 mL default reconstitution volume
300 mcg–1 mg SC or intranasal, short cycles.
Calculator defaults are editable mathematical reference values, not dosing advice. Verify all calculations independently.
Calculate SemaxLaboratory handling
Reconstitution reference
Reconstitute a 5mg vial with 2–5mL bacteriostatic water (or sterile saline for intranasal). Swirl gently.
Storage reference
Lyophilised: 2–8°C, stable 18–24 months. Reconstituted: 2–8°C, protect from light, use within 30 days.
Minimum documentation standard
- Record the lot identifier and review its matching analytical documentation.
- Use aseptic technique and record diluent, final volume and calculated concentration.
- Label preparation date, storage conditions and any light or freeze–thaw restrictions.
- Inspect before each use and investigate unexpected colour, clarity or particulate changes.
Limitations & safety
Most efficacy data is from Russian clinical literature; Western RCT data is limited.
Overstimulation, irritability or headache reported at higher doses.
Intranasal administration may cause transient nasal irritation.
Research use only
This field note is an educational literature summary, not medical advice or a recommendation for human use. Safety statements are limited by the quality and duration of the available evidence.
Continue reading